Table 1.
Clinical characteristics of subjects with high and low BNP.
| Variables | All subjects | Low BNP | High BNP | P value |
|---|---|---|---|---|
| n = 3494 | n = 3347 | n = 147 | ||
| Age (years) | 62 ± 10 | 62 ± 10 | 72 ± 8 | <0.0001 |
| Men/women | 1562/1932 | 1484/1863 | 78/69 | 0.0373 |
| Previous CVD, n (%) | 459 (13%) | 394 (12%) | 65 (44%) | <0.0001 |
| Previous cancer, n (%) | 74 (2.1%) | 70 (2.1%) | 4 (2.7%) | 0.6038 |
| Previous liver disease, n (%) | 82 (2.3%) | 80 (2.4%) | 2 (1.4%) | 0.4196 |
| Smoking, n (%) | 1121 (32%) | 1065 (32%) | 56 (38%) | 0.1106 |
| Alcohol consumption, n (%) | 1454 (42%) | 1390 (42%) | 64 (44%) | 0.6289 |
| Hypertension, n (%) | 1278 (37%) | 1196 (36%) | 82 (56%) | <0.0001 |
| Diabetes mellitus, n (%) | 241 (7%) | 224 (7%) | 17 (12%) | 0.0225 |
| Systolic BP, mmHg | 134 ± 16 | 134 ± 16 | 138 ± 17 | 0.0016 |
| Diastolic BP, mmHg | 80 ± 10 | 80 ± 10 | 80 ± 10 | 0.6310 |
| HbA1c, % | 5.7 ± 0.7 | 5.7 ± 0.7 | 5.7 ± 0.7 | 0.1783 |
| FBS, mg/dL | 95 ± 17 | 95 ± 17 | 96 ± 15 | 0.6199 |
| eGFR, mL/min/1.73 m2 | 82 ± 16 | 82 ± 16 | 71 ± 19 | <0.0001 |
| Log H-FABP, ng/mL | 1.24 ± 0.43 | 1.23 ± 0.43 | 1.56 ± 0.39 | <0.0001 |
| AST, IU/L | 24.6 ± 8.3 | 24.9 ± 12.3 | 26.2 ± 9.6 | 0.2329 |
| ALT, IU/L | 22.9 ± 11.6 | 23.5 ± 14.2 | 20.9 ± 11.3 | 0.0273 |
| γ-GTP, IU/L | 35 ± 42 | 36 ± 47 | 39 ± 52 | 0.3517 |
| AST/ALT ratio | 1.18 ± 0.34 | 1.17 ± 0.34 | 1.38 ± 0.43 | <0.0001 |
Data are expressed as mean ± standard deviation or number (%).
ALT, alanine transaminase; AST, aspartate transaminase; BNP, brain natriuretic peptide; BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; FBS, fasting blood sugar; γ-GTP, gamma glutamyl transpeptidase; HbA1c, glycosylated hemoglobin A1c; H-FABP, heart type fatty acid binding protein.